Semaglutide and urinary tract infections: what you need to know

Step 1: check what the trial data actually recorded

The STEP 1 trial, published in the New England Journal of Medicine, randomised over 1,900 adults with obesity and followed them for 68 weeks on semaglutide 2.4mg or placebo. Gastrointestinal effects (nausea, diarrhoea, constipation) emerged as the dominant adverse-event category. Urinary tract infections were recorded as an adverse event in some participants, but the rates in the semaglutide and placebo arms were close enough that the medicine was not identified as a cause.

That matters, because it tells you that if you are on Wegovy and develop a UTI, the medicine is unlikely to be the direct driver. UTIs are common in the general population regardless of treatment — around one in three women will have one before the age of 24, and recurrence rates are high. Attributing any coincident illness to a new medicine is a very human instinct, and an understandable one, but the data does not support semaglutide as a UTI trigger in the way that, say, SGLT-2 inhibitors (a different diabetes medicine class) are linked to urogenital infections.

You can review the NHS medicines page for semaglutide for a current summary of known side effects; urinary tract infection does not appear in the common or serious categories.

Step 2: separate UTI symptoms from semaglutide's actual urinary effects

Some people on semaglutide notice changes to how often they urinate, particularly in the first few weeks. This is more plausibly connected to the medicine's mechanism than a UTI is. Semaglutide slows gastric emptying and changes fluid distribution as appetite and intake fall. Reduced calorie and fluid intake can alter urine concentration; some people drink less without realising it, which affects both urinary frequency and, separately, can make the bladder environment marginally more hospitable to bacteria.

The distinction matters practically. A UTI typically brings a burning sensation on urination, urgency, cloudy or strong-smelling urine, and sometimes pelvic discomfort or low-grade fever. Changed urinary frequency without those features is a different picture. If you are unsure which is happening, our page on semaglutide and urination changes goes through that difference in more detail, and why urinary frequency can shift on semaglutide is also worth reading if frequency alone is the concern.

Neither situation warrants adjusting your dose yourself. That decision belongs with your prescriber.

Step 3: know when to seek help, and what to tell your clinician

If you have UTI symptoms (burning on urination, frequency, urgency, cloudy urine, or discomfort in the lower abdomen) see your GP or call 111. A UTI needs assessment and, if confirmed, likely treatment with antibiotics. It does not require you to stop semaglutide unless your clinician advises otherwise, but they do need to know you are taking it.

Separately, the MHRA's Yellow Card scheme exists precisely for situations like this: if you suspect any medicine is contributing to a symptom, reporting it helps build the national safety picture. You do not need a confirmed link to report, a suspected one is enough.

Tell your clinician your current semaglutide dose, how long you have been on it, when the urinary symptoms started, and whether you have had UTIs before. That timeline helps distinguish coincidence from a potential pattern. If you are also on other medicines that affect kidney function or urine output, make sure those are on your clinician's list too.

For a broader look at how semaglutide interacts with infection risk and immune function, our page on semaglutide and infection covers the wider evidence. The mechanism behind semaglutide is also useful background if you want to understand why some of these indirect effects occur.

How this fits into deciding whether semaglutide is right for you

If you are reading this before starting treatment rather than during it, the UTI question is worth holding in context. Semaglutide is a prescription-only medicine that requires a clinical assessment before it is prescribed. A prescriber reviewing your case will look at your full medical history, including recurrent UTIs, kidney conditions or anything else that might be relevant, before deciding whether treatment is appropriate and at what starting point.

If you have a history of recurrent UTIs or kidney infections, that is exactly the kind of detail to mention during your consultation. It does not automatically rule out treatment, but it shapes the clinical conversation. You can find out about Wegovy in full (including its licensed uses, eligibility and what private treatment involves) or explore other weight-loss treatment options if you want to compare what is available.

A word on cost: if you are weighing up whether private treatment makes financial sense, our Wegovy price comparison page sets out what a transparent private price should include and what the UK market currently looks like, without dressing it up. Worth reading before you decide.

If any of this raises questions specific to your situation, the straightforward next step is to start your free consultation with our prescribers. A real clinician reads every submission the same day.